Historique de carrière de Todd C. Zankel
Anciens postes connus de Todd C. Zankel
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Raptor Pharmaceuticals Corp.
 Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | Directeur Technique/Scientifique/R&D | 01/10/2009 | 01/10/2009 |
| Fondateur | 01/10/2009 | 01/10/2009 | |
| BIOMARIN PHARMACEUTICAL INC. | Directeur Technique/Scientifique/R&D | 01/01/1997 | 01/01/2005 |
| RAPTOR PHARMACEUTICAL CORP | Fondateur | 29/09/2009 | - |
| Raptor Pharmaceutical, Inc. | Directeur Technique/Scientifique/R&D | 01/01/2006 | - |
| Fondateur | 24/11/2010 | - |
Formation de Todd C. Zankel
| The Reed Institute | Undergraduate Degree |
| The Trustees of Columbia University in The City of New York | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 7 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 3 |
| Founder | 3 |
| Undergraduate Degree | 1 |
Sectorielle
| Health Technology | 5 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
| Raptor Pharmaceutical, Inc. | Health Technology |
Horizon Pharmaceutical LLC
 Horizon Pharmaceutical LLC Pharmaceuticals: MajorHealth Technology Horizon Pharmaceutical LLC engages in the development of transformative treatments for people affected by rare and debilitating diseases. It offers PROCYSBI, a delayed-release capsule, which is used for the management of nephropathic cystinosis in adults and for six years and older children. The company was founded by Christopher M. Starr and Todd C. Zankel on April 29, 2002 and is headquartered in Novato, CA. | Health Technology |
Raptor Pharmaceuticals Corp.
Raptor Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to research and development a novel drug and drug-targeting platform intended to initially treat a variety of brain disorders, neurodegenerative diseases, cancer and metabolic diseases through the proprietary use of a natural human protein known as the receptor-associated protein (RAP). The Group is in development stage. The Group acquired Convivia, Inc in 2007. | Health Technology |
- Bourse
- Insiders
- Todd C. Zankel
- Expérience
